Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 577.50
Bid: 565.00
Ask: 590.00
Change: -17.50 (-3.00%)
Spread: 25.00 (4.425%)
Open: 582.50
High: 565.00
Low: 565.00
Prev. Close: 582.50
ELIX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

1 Feb 2022 07:00

RNS Number : 1912A
Elixirr International PLC
01 February 2022
 

ELIXIRR INTERNATIONAL PLC

("Elixirr", the "Company" or the "Group")

Trading Update

 

Elixirr International plc (AIM:ELIX), an established, global award-winning challenger consultancy, is pleased to provide an update on trading for the year ended 31 December 2021.

 

Trading through to the end of 2021 continued to be strong. The Group has continued to support its clients to address their key challenges, with Elixirr's services in relation to digital transformation and innovation in high demand.

 

Subject to the completion of the audit for the year ended 31 December 2021, the Group expects to record revenue of approximately £50.5m, above the market expectation of £47-50m. Adjusted EBITDA is expected to be approximately £15.5m, above the market expectation of £15.0m and within the range of 30-32% of revenue previously announced.

 

As at 31 December 2021, the Group had no debt with cash balances in excess of £31m.

 

The Group has continued to make good progress on all four of its strategic growth pillars, including:

· Stretching our current partner team - we achieved organic revenue growth in excess of 30% during 2021, including growth of approximately 100% in our US business

· Promoting partners from within the firm - we have promoted two experienced principals to partner on 1 January 2022

· Hiring new partners - six experienced partners joined the business over the course of 2021, with a number of them focused on accelerating the growth of our US business

· Buying complementary businesses - we completed the acquisition of The Retearn Group Limited in April 2021 and are seeing good traction with selling their procurement and self-funded transformation services into our client base. We remain focused on inorganic growth and are continuing to explore a number of other attractive acquisition opportunities with companies specialising in solving Board room issues, including in the US market which is the fastest growing part of our business.

The Directors expect further organic revenue and Adjusted EBITDA growth in 2022. A more detailed update on expectations for 2022 will be provided by the Directors in conjunction with the release of the full year results for the year ended 31 December 2021 on 4 April 2022.

 

For further Information please contact:

 

Elixirr International plc

Stephen Newton, CEO

Graham Busby, CFO

 

 

 

 

Public and Investor Relations contacts:

Caroline Pitt

 

finnCap Ltd (Nominated Adviser & Sole Broker)

Christopher Raggett, Kate Bannatyne (Corporate Finance)

Alice Lane, Sunila De Silva (ECM)

 

 

 

investor-relations@elixirr.com

 

 

+44 (0)20 7220 0500

 

 

About Elixirr International plc

Elixirr is an established global award-winning management consultancy, challenging the larger consultancies by delivering innovative and bespoke solutions to a repeat, globally-recognised client base.

Elixirr was founded in 2009, by Stephen Newton, Graham Busby, Ian Ferguson, Andy Curtis and Mark Goodyear, experienced business advisors who identified a market opportunity to provide bespoke, personal services as a 'challenger' to the traditional consultancy businesses in the market. Elixirr guides its clients to overcome challenges such as: future-proofing against technological disruption; development and roll-out of new propositions, products and services; incubating new businesses; navigating a more complex and multinational regulatory environment; and project management and implementation of major change programmes.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUASSRUSUAOAR
12
Date   Source Headline
26th Jan 20247:00 amRNSDirector Dealing
8th Jan 20247:00 amRNSTrading Update and Change to Dividend Policy
11th Dec 20237:00 amRNSAcquisition of Insigniam LLC and Insigniam SAS
18th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSAcquisition of Responsum, Inc.
13th Jun 202310:45 amRNSResult of AGM
24th May 20231:31 pmRNSHolding(s) in Company
19th May 20237:00 amRNSPosting of Annual Report and Accounts
10th May 20233:00 pmRNSDirector/PCA Dealings
26th Apr 20237:00 amRNSGrant of Share Options
12th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
4th Apr 20233:00 pmRNSDirector Dealing
3rd Apr 20239:15 amRNSDirector Dealing
3rd Apr 20237:00 amRNSFinal Results
28th Mar 20237:00 amRNSInvestor Presentation
27th Feb 20239:05 amRNSSecond Price Monitoring Extn
27th Feb 20239:00 amRNSPrice Monitoring Extension
27th Feb 20237:00 amRNSTrading Update
24th Feb 20232:05 pmRNSSecond Price Monitoring Extn
24th Feb 20232:00 pmRNSPrice Monitoring Extension
24th Feb 202311:05 amRNSSecond Price Monitoring Extn
24th Feb 202311:00 amRNSPrice Monitoring Extension
29th Nov 20221:15 pmRNSInvestor Presentation
11th Nov 20227:00 amRNSDirector Dealing
20th Oct 20227:00 amRNSPCA Dealing
6th Oct 20227:00 amRNSPurchase of Shares by Employee Benefit Trust
20th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
29th Jul 20224:41 pmRNSSecond Price Monitoring Extn
29th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20221:45 pmRNSPDMR/PCA Dealing
7th Jul 202211:15 amRNSPCA Dealing
13th Jun 20221:00 pmRNSResult of AGM
19th May 20227:00 amRNSPosting of Annual Report & Accounts
29th Apr 20224:07 pmRNSResult of Secondary Placing
28th Apr 20224:06 pmRNSProposed Secondary Placing
8th Apr 20224:15 pmRNSDirector/PDMR Shareholding
4th Apr 20227:00 amRNSFinal Results
18th Mar 20227:00 amRNSAcquisition of iOLAP and FY2022 Earnings
1st Feb 20227:00 amRNSTrading Update
30th Nov 20217:00 amRNSDirector/PDMR Shareholding
13th Oct 202111:41 amRNSResult of Secondary Placing
13th Oct 20217:00 amRNSProposed Secondary Placing
27th Sep 20217:00 amRNSInterim Results
17th Jun 20218:13 amRNSDirector/PDMR Shareholding
16th Jun 202112:21 pmRNSResult of AGM
16th Jun 20217:00 amRNSAGM Statement
24th May 20217:00 amRNSPosting of Annual Report & Notice of AGM
12th May 20213:52 pmRNSResult of Secondary Placing
12th May 20212:09 pmRNSProposed Secondary Placing
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.